J Clin Oncol 2009 Oct 1
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Related Questions
New answer by Medical Oncologist at Mayo Clinic (March 1, 2018)
Possibly...there seems to be an association between the intensity of uptake and response to somatostatin analogs (SSAs) in patients with G2/G3 NETs. Almost all express somatos...
New answer by Medical Oncologist at Mayo Clinic (May 16, 2021)
As far as I am concerned, the drugs are equally effective, assuming the drugs get delivered correctly. The advantages of lanreotide are, as others have mentioned, a more relia...
If so, how long would you treat?
New answer by Medical Oncologist at Mayo Clinic (March 30, 2023)
I generally would not unless there was a substantial amount of residual disease per se and/or there were symptoms of the carcinoid syndrome which is very unlikely after near t...
New comment by Medical Oncologist at Mayo Clinic ( September 11, 2023)
I would be careful with a h/o SBO, especially of peritoneal mets, and perhaps be more inclined to start therapy but if there was a cause of the SBO (tumor, adhesions, fibrosis...